Biogen Inc. (BIIB) Earnings Call Transcript & Summary
October 25, 2022
Earnings Call Speaker Segments
Mike Hencke
executiveHello everyone, and thanks for joining us for Biogen's Q3 2022 earnings call. To get started, please head over to the Investors area of biogen.com, where you'll find the earnings release along with the related financial tables — this includes our GAAP figures and the reconciliation between GAAP and non-GAAP measures we'll be covering today. Tables one and two contain our GAAP financials, while table four provides a reconciliation from GAAP to non-GAAP results. In our view, non-GAAP results give a clearer picture of the business's ongoing economics and show how we steer things internally. Slides are also up on our site, and they track the topics we'll walk through on this call. I want to note that forward-looking statements will be part of what we say today, and those rest on what we currently expect and believe. Such statements carry certain risks and uncertainties, so actual outcomes could end up differing materially. For more specifics, please review the risk factors laid out in our SEC filings. Joining me on the call today are our Chief Executive Officer, Mr. Vounatsos; Dr. Priya Singhal, Interim Head of Research and Development; and our CFO, Mike McDonnell. One reminder: during Q&A, we ask that you please stick to a single question. I'll hand things over now to Michel.
Michel Vounatsos
executiveHello, everyone, and thanks for being with us today. This marks a thrilling moment for Biogen. Along with major strides throughout our pipeline — comprising 12 programs that are in Phase 3 or already filed — we keep moving forward with execution, and we're happy to report that we are lifting our guidance for the full year's financials. Let me start by going over the significant headway achieved during this quarter and why we think those steps matter for Biogen. After that, Priya will walk through what's new in R&D, and Mike will cover how we performed in the third quarter. To kick things off, alongside Eisai, we were thrilled to share favorable findings from CLARITY AD, the Phase 3 trial of lecanemab for early Alzheimer's disease. For more than 15 years, Biogen has labored tirelessly to deliver novel therapies for Alzheimer's disease, folding in fresh understanding of disease biology as well as how trials are designed; and now, we're celebrating the favorable CLARITY AD results as a major milestone in treating Alzheimer's disease. Findings from Clarity AD demonstrated multiple important elements of lecanemab's clinical profile, which we think may deliver meaningful advantages to patients. To begin with, giving lecanemab produced a highly statistically significant lessening of clinical decline starting at six months, which grew larger across the 18-month duration of the study in absolute terms, aligning with a disease-modifying impact. Next, the trial succeeded on every key secondary endpoint. That covers combined measures of cognition plus activities of daily living, like handling personal finances, carrying out household chores, and going out of the home without help. Third, the rate of area in Clarity AD fell within what was expected. With an FDA ruling on accelerated approval anticipated by January 6 of next year, and Eisai's intention to seek traditional approval in the US, EU and Japan by the close of Q1 2023, lecanemab could become the first treatment approved globally that slows Alzheimer's disease progression. We're eager to collaborate with Eisai as they keep working with regulators and CMS, aiming to make sure that individuals with Alzheimer's disease can obtain vital new treatments. We think the Clarity AD findings highlight the strides we're making in battling Alzheimer's. Yet Biogen won't halt its efforts here. We intend to leverage what we've learned so far as we keep pushing forward a varied pipeline of possible Alzheimer's treatments. That encompasses two clinical-stage assets aimed at tau pathology, BIIB080, our antisense oligonucleotide that's Phase 2 ready, plus BIB113, a small molecule in Phase 1. Beyond Alzheimer's, Biogen holds key possibilities in other therapeutic fields, where the unmet medical need is still substantial. That includes depression, where, working with Sage, we're pressing ahead with the regulatory submission for zuranolone in both major depressive disorder and postpartum depression, featuring a novel mechanism of action, efficacy seen starting at three days, and a steady safety and tolerability profile throughout eight clinical studies, we believe zuranolone, should it gain approval, might become a meaningful new treatment for depression. Next, the FDA has cleared our submission for tofersen in SOD1-ALS through the accelerated approval route, and given it priority review. Although the trial failed to hit its primary endpoint at 6 months, extended tracking has revealed that individuals continuing on tofersen saw a gradual pace of worsening across important clinical metrics, such as lung function, muscle strength and quality of life. These findings genuinely give us hope in a disease this devastating and deadly, and we await an FDA ruling anticipated by April of next year. We think this near-term opportunity, together with fresh biosimilar launches, could fuel renewed growth and put us in position to hold five key franchises by 2025. Beyond that, we foresee possible added growth drivers during the mid to late 2020s in fields like Parkinson's disease, lupus and stroke, each with programs now in Phase 3. On the whole, we think we've reached a turning point in CNS drug discovery and development, and these latest events reflect major strides being made in neuroscience. For years, Biogen has been growing our know-how and capabilities here, and we think we're well positioned to stay a leader in neuroscience as we strive to bring in the next new wave of CNS therapeutics while also moving forward our portfolio in specialized immunology, where we have 4 late-stage studies in lupus. I'll now hand the call over to Priya for a more thorough update on our recent R&D progress.
Priya Singhal
executiveMichel, thank you, and good morning, everyone. During the quarter that just closed, as Michel mentioned, we hit several exciting R&D milestones that give a substantial lift to the promise of our pipeline, which holds 30 programs, with 12 of those either in Phase 3 or already filed, all focused on delivering impactful new therapies to patients and driving renewed growth for the company. Let me start with Alzheimer's disease. Together with Eisai, we were delighted to share positive results from the Clarity AD study, which evaluated lecanemab in early Alzheimer's disease. The primary endpoint involved a change from baseline on CDR Sum of Boxes, a well-recognized measure of cognition and function in Alzheimer's disease. That primary endpoint was met, and at 18 months lecanemab lowered clinical decline on the CDR Sum of Boxes relative to placebo by 0.45, a treatment difference of 27%. We also saw a highly statistically significant reduction on the CDR Sum of Boxes versus placebo as early as six months; in our view this shows a rapid onset of efficacy and a meaningful change on the CDR Sum of Boxes versus placebo. In addition, the effect on the CDR Sum of Boxes grew across the 18-month study period on an absolute basis, which suggests lecanumab was exerting a disease modifying effect. All key secondary endpoints were met as well, reinforcing lecanumab's impact on cognition and function. This includes a decrease in amyloid plaques in the brain that was statistically significant, along with other clinical measures like the ADCS-MCI-ADL, which is a caregiver-reported evaluation of daily living activities compared to placebo. In our view, these efficacy findings, together with an overall ARIA incidence rate observed at about 21%, highlight lecanemab's potential to become a leading disease-modifying therapy for Alzheimer's disease. Eisai is set to share the Clarity AD study data at CTAD in November and plans to release the results in a peer-reviewed medical journal. Right now, the lecanemab application through the accelerated approval pathway is being reviewed, with a PDUFA date set for January 6, 2023. The FDA is also on board with using Clarity AD as a confirmatory trial to establish lecanemab's clinical benefit. With that in mind, once the FDA gives a favorable accelerated approval decision, Eisai intends to submit for traditional approval of lecanemab in the US at the earliest opportunity — that submission should come by the close of Q1 2023, and marketing authorization filings for the EU and Japan are likewise anticipated by the end of Q1 2023. Eisai has additionally been in discussions with the Centers for Medicare and Medicaid Services as they aim to broaden patient access. In addition to those efforts around regulation and access, we're working with Eisai on a broad development plan for lecanemab. That plan covers several things. First, there's the AHEAD 3 to 45 pre-clinical study that's already underway, which looks at lecanemab given earlier in the disease process — specifically when amyloid pathology has appeared but cognitive impairment hasn't yet begun. After that, we're looking into whether the maintenance dosing schedule could be modified so that lecanemab is given less frequently over time. We're also developing a subcutaneous form of lecanemab. Back at AAIC this year, Eisai shared bioavailability findings from a Phase I trial that compared intravenous with subcutaneous administration, along with modeling and simulation results indicating that a weekly fixed subcutaneous dose of 720 milligrams could potentially deliver exposure and efficacy similar to the existing IV form, while possibly decreasing how often ARIA occurs. Armed with that data, our current focus is on preserving our long-term leadership role in Alzheimer's disease. Our portfolio leads the industry in tackling amyloid and tau pathologies, and we also have a pre-clinical multi-target, multi-modality pipeline aimed at a wide spectrum of Alzheimer's disease biology. Let me shift to neuropsychiatry, where during this quarter, Biogen and Sage shared fresh findings backing zuranolone's potential, should it gain approval, as an innovative therapy for major depressive disorder as well as postpartum depression. That includes a refreshed look at the ongoing open-label longitudinal SHORELINE Study in MDD, revealing that the medium time to onset first — pardon me, the median time to first repeat treatment among patients responding to the initial 14-day course came to 135 days in the 30-milligram group and 249 days in the 50-milligram group. In our view, this data bolsters the argument that zuranolone could become an important new choice for people suffering from depression. Together with Sage, we are continuing to move forward on one US regulatory filing for zuranolone covering both MDD and PPD, and that submission ought to be finished by the end of this year. Now turning to our neuromuscular work. Twelve-month findings from the Phase III VALOR study, along with its open-label extension, which evaluated tofersen in SOD1-ALS, have just been published in the New England Journal of Medicine. SOD1-ALS is an uncommon, progressive genetic form of ALS for which no targeted therapy currently exists. According to the published findings, patients starting tofersen in VALOR saw slower decline rates across key measures of function, muscle strength, and quality of life compared with those who switched from placebo to tofersen when the open-label extension began six months afterward. Additionally, tofersen produced a strong and lasting drop in neurofilament, a marker of neuronal injury and neurodegeneration; in July, the FDA accepted the tofersen submission under accelerated approval with priority review. After that, we provided responses to an FDA information request, which the agency deemed a major amendment to the application, necessitating extra review time. Consequently, the review timeline has been lengthened by three months, and an FDA decision is now anticipated by April 25, 2023. Now for movement disorders: working with Denali, we began our second late-stage study of BIIB122, which is a small molecule that inhibits LRRK2. In the Phase 3 LIGHTHOUSE study, we'll be evaluating BIIB122 among patients who have a confirmed pathogenic LRRK2 mutation. Because LRRK2 activity is believed to regulate lysosomal function along with the biological pathway underneath it that plays a role in Parkinson's disease, we're also advancing the Phase 2b LUMA trial in idiopathic Parkinson's disease, which started earlier this year. Moving on to specialized immunology. We were happy to announce the launch of the Phase 2/3 trial of Litifilimab, also called BIB059, in cutaneous lupus erythematosus, or CLE. In both parts of the earlier Phase 2 LILAC study of Litifilimab, the main goals were achieved, with safety and efficacy being evaluated in patients who had CLE and systemic lupus erythematosus, or SLE. Recently, the full Phase 2 results were published as two separate papers in the New England Journal of Medicine. Our mid- to late-stage pipeline in specialized immunology is anchored by the Phase 2/3 study in CLE, and it also includes three Phase 3 studies in SLE—two involving Litifilimab and one involving dapirolizumab pegol, which is being developed together with UCB. As we look ahead, there are several exciting opportunities on the horizon. These include the potential to bring new treatments to patients in Alzheimer's, depression, and SOD1-ALS; kicking off mid- to late-stage studies in Alzheimer's disease and stroke; and getting a proof-of-concept readout in broad ALS. In short, we believe the progress we've made recently demonstrates core aspects of how we approach R&D at Biogen. That includes focusing on targets and biology with genetic validation, using novel biomarkers to improve our understanding of disease biology and confirm target engagement, and our ability to select the appropriate therapeutic modality for each specific disease area or target. Combining these guiding ideas with the ongoing work we're doing to set priorities, our view is that this may raise the odds of succeeding in therapeutic areas where unmet need remains significant. At this point I'll turn things over to Mike.
Michael McDonnell
executivePriya, thanks for that, and good morning to all of you. I'll walk through a few key points on how we did financially in the third quarter, plus where our full year 2022 guidance now stands. Just so we're clear, every comparison I make financially is against the third quarter of 2021. Third quarter total revenue came in at $2.5 billion, down 10% at actual currency and down 8% at constant currency. Non-GAAP diluted EPS for the third quarter landed at $4.77, which was flat against the third quarter of 2021. Total MS revenue, which includes OCREVUS royalties, reached $1.6 billion, a decline of 11% at actual currency and 9% at constant currency. Global TECFIDERA revenue was $339 million, falling 32% at actual currency and 30% at constant currency. We're still seeing TECFIDERA erode in the US because of generics, along with an impact from generics outside the US, mainly in Germany. New generic launches in the EU keep coming. Earlier this month, the advocate general of the European Court of Justice gave a non-binding advisory opinion. Should the court adopt that advisory opinion, we'd expect TECFIDERA to hold statutory market protection until at least February of 2024. The court has no deadline for issuing its final decision, though our understanding is that roughly three to five months following the advocate general's opinion being issued is typical. On a separate note, we're filing actions to enforce our recently granted European TECFIDERA dosing patent, which runs out in 2028. We've managed to obtain preliminary injunctions in certain countries and failed to do so in others, Germany and France among them. Until we either confirm TECFIDERA's entitlement to statutory market protection in the EU, or successfully assert our patent, generics are free to keep selling in countries where no preliminary injunctions are in place. Global VUMERITY revenue hit $138 million, up 14% at actual currency and 15% at constant currency. US VUMERITY revenue rose 6% on higher volumes, partly offset by increased discounts and allowances. VUMERITY is feeling pressure from both payers and the shrinking oral segment of the market in the United States. We're continuing to work with our contract manufacturing supplier on potential supply constraints for VUMERITY. We've identified the root cause, implemented manufacturing changes required to resolve the issue, and are now working to secure necessary related regulatory approvals; no supply shortage is anticipated in 2022, and right now we're focused on rebuilding adequate inventory with the goal of ensuring supply and reinitiating new country launches in 2023. Global TYSABRI revenue was $505 million, down 3% at actual currency and 1% at constant currency. US TYSABRI revenue took a negative hit from higher discounts and allowances and lower volume. Outside the US, we were pleased to see continued patient growth as well as good uptake of the subcutaneous formulation in the EU, which has now been launched in over 25 markets with an average conversion rate of approximately 40%. Even though the matter patents covering the composition of TYSABRI have lapsed, additional patents remain that pertain to how TYSABRI is produced and utilized, and those are set out in our 10-K. We intend to keep defending this intellectual property, which includes taking legal action against Sandoz here in the United States. Interferon revenue worldwide came to $336 million, a drop of 13% in actual currency terms and 12% on a constant currency basis, pressured by the ongoing migration away from injectable options toward oral treatments or therapies with high efficacy. Turning to SMA. SPINRAZA's worldwide revenue reached $431 million, down 3% as reported and up 2% in constant currency; within the US, SPINRAZA revenue matched the prior year's figure, and we think there may be indications of stabilization domestically. Beyond the US, once negative currency effects are excluded, revenue grew thanks to higher volumes in select Asian markets plus some favorable pricing trends, though competition and shipment timing partly offset that. On the whole, our view remains that SPINRAZA could expand over time. Now to Biosimilars. Revenue there was $188 million, falling 7% at actual currency and 4% at constant currency; sales volumes rose, but that gain was erased by unfavorable pricing and adverse currency movement. Our expectation is still for a step-by-step rollout of BYOOVIZ, with a more substantial revenue contribution anticipated starting in 2023. Anti-CD20 revenue totaled $417 million, unchanged from a year earlier. Royalties from OCREVUS rose 6%, offset by ongoing RITUXAN erosion stemming from biosimilar rivals. Shifting now to expenses and the balance sheet. Non-GAAP cost of sales for the third quarter came in at $470 million, which factors in $12 million tied to idle capacity charges. Looking ahead, we anticipate additional strain on gross margins from product mix changes and possible idle capacity charges, mostly tied to the halt in drug product manufacturing for ADUHELM. Non-GAAP R&D spending for the third quarter was $549 million. That compares with $702 million during the same quarter of 2021, a figure that had included roughly $165 million of upfront payments tied to business development deals along with costs for closing out clinical trials. Non-GAAP SG&A stood at $562 million. That's versus $651 million in the third quarter of 2021. The reduction in SG&A came mainly from cost savings programs. Collaboration profit sharing in the third quarter was a net expense of $45 million, driven largely by our partnership with Samsung Bioepis. Non-GAAP other expense totaled $55 million, mostly from interest expense. During the third quarter, cash flow from operations came to $661 million. Capital expenditures were $59 million, and free cash flow reached $602 million; we bought back 1.2 million shares of the company's common stock in the quarter, spending $250 million at an average price of $214 per share. We closed the quarter holding $5.8 billion in cash and marketable securities, $6.3 billion in debt, and roughly $500 million in net debt. Also worth noting, during Q3 we brought in $583 million in net proceeds after selling a Cambridge building, which is part of our effort to optimize our office footprint. On top of that, in October we disbursed $900 million along with fees and expenses in order to settle the qui tam litigation that had been previously disclosed. Keep in mind, we anticipate bringing in another $1.25 billion across the coming 1.5 years from divesting our equity stake in Samsung Bioepis, with roughly $813 million of that arriving in April of next year. All told, our financial standing remains very robust, with substantial cash and financial capacity, among which is a $1 billion revolving credit facility that has not been drawn, available to put toward growing the business over the long-term. Before moving on to our updated guidance, I'd like to share a few remarks regarding lecanemab. It's exciting for us to be working alongside Eisai on this significant opportunity through a global 50 to 50 profit sharing agreement. As a reminder, Biogen holds the right to co-commercialize and co-promote lecanemab together with Eisai, who possesses final decision-making authority. Once approval comes through, our portion of profits or losses will be recorded as a component of other revenue. During the initial quarters of the launch, the lecanemab piece of other revenue could turn out negative. For additional accounting considerations, please refer to Slide 26 in our earnings presentation. Now let me talk about our updated full-year 2022 guidance. We're raising our full-year revenue guidance from the earlier range of $9.9 billion to $10.1 billion, moving to a new range of $10 billion $10.115 billion, and raising our full year non-GAAP diluted EPS guidance from the earlier range of $15.25 to $16.75, moving to a new range of $16.50 to $17.15. This bump in guidance stems mainly from stronger-than-anticipated topline performance along with ongoing cost management. Our guidance ranges for non-GAAP R&D expense, non-GAAP SG&A expense, and our non-GAAP tax rate all remain the same as prior guidance. Keep in mind, we generally experience seasonally higher SG&A spend during the fourth quarter. This guidance presumes that foreign exchange rates as of September 30th will stay in effect through the rest of the year, net of hedging activities; this financial guidance also presumes continued declines in RITUXAN revenue because of biosimilar competition, along with continued erosion of TECFIDERA revenue stemming from generic entry. For other important guidance assumptions, please see our press release; in summary, we keep executing well throughout our core business and are happy to be raising our financial guidance for the year. We're enthusiastic about the recent lecanemab readout and believe our diversified pipeline spanning neuroscience, specialized immunology, and biosimilars has the potential to bring Biogen back to growth over time as we keep building a multi-franchise portfolio. As always, we stay focused on creating long-term value for our shareholders; and with that, we'll now open the call for questions.
Umer Raffat
analystMorning, everyone. My question concerns where things stand with Eisai. Investors have been asking about this quite a bit. I was simply wondering whether you might address what the current state of that relationship is, whether you anticipate Eisai permitting you to handle commercialization, and whether any contractual conflicts or anything of that nature have arisen. Thanks so much.
Michel Vounatsos
executiveAppreciate that, Umer. What I can say is that for a number of years now, this partnership has been extremely solid. On a very routine basis, I get the chance to sit down and get aligned with the person who holds the equivalent role at their company. In the next few days, I'll be doing that again. Our teams collaborate quite closely. Whenever we talk, co-commercialization and co-marketing come up for discussion, and nothing has been settled on that front as of yet; but on the whole, this is a healthy, strong relationship. Mike, anything you'd like to add?
Michael McDonnell
executiveNo, I believe that's everything. I'd add that while we collaborate on the plan for commercialization, it's clear Eisai holds the ultimate authority to decide, yet profits are split evenly at 50 to 50. And jointly, we're looking forward to the CTAD presentation coming up, where they'll share more in-depth findings from the study.
Brian Abrahams
analystGood morning, and thanks for the question. Congratulations on the quarter and on the lecanemab data. I'm interested in how you see reimbursement access for lecanemab shaping up under accelerated approval compared with full approval. And I suppose I'm asking, given the CMS discussions you and your partner have been having, where things currently stand on whether the topline results from Clarity AD would meet CMS' requirements for high-level evidence, enough to support NCD reconsideration if there's an accelerated approval. Thank you.
Michel Vounatsos
executiveThanks for raising this important point. In my view, everything hinges on how strong the evidence is; the top line results on the primary and secondaries have us quite pleased. We're all eager for CTAD and for an upcoming publication, so we can gauge the level of evidence CMS will consider, which will determine the path forward. Priya?
Priya Singhal
executiveThanks, Michel. You've got it precisely right. Let me also mention that the NCD lays out a few different scenarios. Under the accelerated approval pathway, coverage basically applies only within a randomized controlled trial setting, which amounts to essentially no coverage at all. With traditional approval, though, the NCD seems to present a spectrum of possibilities — including coverage through a prospective comparative study approved by CMS, registries among them. How strong and rigorous such a study needs to be will be tied to how strong and rigorous the randomized controlled trial was that supported the eventual traditional approval. Given that, our confidence in the evidence's strength is quite high. As you're aware, the primary endpoint was met, showing a treatment difference of 0.45, which worked out to 27% versus placebo with lecanemab; on top of that, every secondary endpoint was hit with a high degree of statistical significance. I'd also note that roughly 25% of participants came from an underrepresented population. So our view is that the design is very solid and the findings are quite encouraging. What remains will become clear over time, and Eisai has already begun engaging with CMS to talk it through. You asked specifically about reconsideration, so let me note something there: in the final scenario, the final NCD that came out stated CMS would move with urgency, and a reconsideration could potentially be taken up. From a historic precedent standpoint, that might take nine to 12 months; however, my sense is that in this case they've indicated they would act with urgency. That would mean full coverage without requiring prospective comparative studies. So I think we need to await the CTAD data and keep the engagement going.
Salveen Richter
analystMorning, and thanks for fitting in my question. Given what we've seen from the lecanemab data, could you explain your current approach to business development and how you're ranking the portfolio?
Michel Vounatsos
executiveSure — I'd say we continue to be quite active when it comes to BD, meaning we're constantly assessing it. The portfolio, clearly, is in good shape. As we mentioned in the prepared remarks, there are 12 Phase III programs for products already filed, and we're gearing up for AD, ALS, MDD and PPD. So everyone here is quite occupied. Even so, BD stays on the table, since there's always room to strengthen the portfolio. Each week we're looking at prospects, and we're moving forward. Over the last few years we've completed more than 30 deals, yet we remain highly active. Priya and Mike?
Priya Singhal
executiveThanks. That’s a really good question, and if I pull back a bit, as Michel said in the prepared comments, we regard ourselves as leaders in Alzheimer’s. We feel we’ve carried out extensive assessment of the scientific hypotheses and the biology. And we’ve built our portfolio so it can tackle both the biology question and the timing question; so on biology, we’ve now achieved success with lecanemab. Earlier, we also saw results with aducanumab, and that reflects the A-beta hypothesis. On top of that, we ran our own trial with the monoclonal antibody targeting tau, and it failed; so we did put that hypothesis to the test with extracellular tau, and now we’re ready to launch our Phase 2 with BIIB080, an antisense oligonucleotide designed to target all post-translational forms of tau. So we think <<inaudible>> we think we have a leading antisense oligonucleotide; we also have BIIB113 in Phase 1, which targets tau aggregation and involves enzymatic inhibition of tau aggregation; so we’re genuinely attempting to go after this across the board — from amyloid and tau pathology. Beyond that, in preclinical work, we also have a number of other biologies we’re examining closely, both in terms of targets and modalities. So I’d say our approach is quite comprehensive. As for timing, I’m very happy that lecanemab is already being studied in preclinical Alzheimer’s disease. That trial is already underway, and it will examine what occurs if you intervene with an anti-amyloid therapy before — at the point when amyloid aggregation is present but symptoms are not. So I think it’s a very comprehensive approach; we won’t stop here. We keep reviewing highly attractive targets; and I believe BD plus internal development will remain important. And last, with lecanemab, we’re evaluating two very important elements in our development plan. Eisai is clearly the leader on this. In the Phase 2 open-label extension, we’re examining maintenance dosing. So what’s the correct frequency to keep preserving the halt in clinical decline progression. And we’re evaluating subcutaneous development in the Phase III open-label extension. So overall, I’d say it’s very, very comprehensive. And I think this is an area where we’ll keep investing in order to win. Thank you.
Michel Vounatsos
executiveMike, do you want to add anything to BD?
Michael McDonnell
executiveNo — the single point I'd toss in briefly is this, and I believe you already hit on it, but let me just mention it fast. When it comes to fresh partnerships or M&A, nothing showed up this quarter, and that shouldn't be interpreted as meaningful; our pipeline remains quite strong, and we keep evaluating many different opportunities. These things really do arrive unevenly, and you ought to anticipate additional deals going forward. Thank you.
Michel Vounatsos
executiveLike Priya put it so well, neurodegeneration is becoming a bigger focus as we privatize, and we're set up to take the lead in AD. We're actively reviewing every target and asset that might be acquired, and looking past that too.
Tim Anderson
analystI actually want to ask about ADUHELM, and it ties into what was said earlier regarding your involvement with lecanemab still being something you're considering. A lot of people seem to believe you've essentially walked away and are no longer doing much of anything with ADUHELM. But based on what I've heard, that might not be accurate. You're continuing to work on a subcu form of the drug. It also sounds like you might still be attempting to find a way to obtain CMS reimbursement for APOE4 carriers. So I'd like to know whether that's correct, and whether it could create some friction with Eisai. To me, it simply doesn't make sense why you wouldn't go all-in on lecanemab rather than staying active with ADUHELM. Thank you.
Michel Vounatsos
executiveSo we will go all-in on lecanemab <<inaudible>>, alongside the excellent partners we have, and we'll do whatever is possible to ensure patients can access the product following the regulatory process. That said, the Clarity AD strengthens the conclusion that clearing aggregated form of a beta <<inaudible>> from the brain may be linked to a reduction in the pace of cognitive decline. That matters a great deal, and it's what we demonstrated with ADU, and we currently have patients receiving doses in the EMBARK study. Priya will share more on that.
Priya Singhal
executiveRight, so honestly there isn't much for me to add here. What I can tell you is that aducanumab remains something we keep evaluating, and no choices have been finalized on that front. At this point, we feel the EMBARK data set will prove extremely useful for the scientific community; the patients involved received aducanumab along with an anti-amyloid therapy across many years. On top of that, since aducanumab became the first product granted accelerated approval, we carry a post-marketing requirement, known as the ENVISION study. So as things stand, ENVISION and EMBARK are both ongoing.
Chris Raymond
analystHey, thanks. Maybe a question tied to the previous one. Your commercial setup for ADUHELM has mostly been taken apart at this point. How should we view the spending ramp for lecanemab infrastructure once January comes? Could you also share what ADUHELM taught you and take us through how you allocate resources for this launch as you go from a possible accelerated approval to full approval? Thanks.
Michel Vounatsos
executiveThanks for asking. I'll begin, and Mike will follow. Given the timeline and the distance between the ADU, NCD decision and the lecanumab readout and then the regulatory process, keeping a big force in place was not reasonable. That would not have been reasonable. So we had no option but to do what we did; now a new page has turned; and alongside the partners, we are evaluating, weighing the benefits — the strength, the relative strength of each company on each continent, because we plan to file for full approval at roughly the same time in the US, in Europe and Japan if we get the accelerated approval early in the year; we are planning the investment, but we are not fully there yet; so we will proceed in a very paced and controlled manner, and we'll go from there. Mike?
Michael McDonnell
executiveYes. To build on that point, as we keep talking with Eisai about how to commercialize this, the profit split is 50-50. As we've mentioned, they hold the final say. There are lessons from what happened with ADUHELM that all of us, obviously, share candidly. And what I'd say is that my confidence is quite high that you'll see spending ramp up in a way that stays much closer to revenue than what occurred with ADUHELM, and clearly, several aspects of ADUHELM went in a direction none of us expected. Still, my confidence is high that we can calibrate this — and Eisai can calibrate this — so that the spending ramp keeps better proximity to revenue than what occurred with ADUHELM.
Michel Vounatsos
executiveLet me add this, if I can — there's a fresh procedure in front of us. A few years back, our assumption was that an accelerated timeline would lead to a product launch, and that turned out to be wrong. So at this point, we have a new procedure that has been laid out, and going forward we will be highly disciplined about how the company's resources get used to scale up.
Matthew Harrison
analystGood morning, and thanks for taking my question. I'd like to ask about something we hear frequently from investors — the possibility that particular subgroups or populations could perform better and account for a meaningful share of the lecanemab topline results. So could you confirm whether, if that were true — say a specific subgroup drove most of the response — you would have flagged it in the topline? Or how should we think about this ahead of CTAD? Thanks.
Priya Singhal
executiveI can take that one. Thanks for the question, Matthew. To sum up, the Clarity AD study achieved its main goal, which was CDR-Sum of Boxes, and the p-value came in at 0.00005. That means the finding was extremely statistically significant. It was also a big study, with roughly 1,800 people taking part, among them members of underrepresented populations, and it succeeded on every secondary endpoint too — those being separate areas of cognition and function. All in all, we view these outcomes as highly favorable and quite encouraging. That said, Eisai has not released specifics from the subgroup analyses, and my sense is that we should hold off until CTAD for additional information on both the primary and secondary endpoints. At this stage, though, my take is that on the whole, our view is simply that patience is required, and the revenue picture we've observed leaves us quite optimistic. As for precisely what will or won't show up, that's something I can't address. In my view, CTAD is where we'll have to wait for that.
Brian Skorney
analystHello, good morning, everybody. I appreciate you taking my question. Could you possibly lay out whatever general schedule exists for subcutaneous lecanemab? I'm simply curious how that path would look and whether your goal might be approval for both initial and chronic dosing, or whether it would instead be a label where patients who began with IV could switch over after some period. Also, any insights gained from your talks with the FDA regarding subcu that you believe could carry forward?
Priya Singhal
executiveBrian, thank you. Broadly speaking, what I'm able to share is that this represents a highly significant element of the long-term, thorough clinical development strategy for lecanemab; moreover, work on the subcutaneous formulation is already underway within the Phase 3 open-label extension. Additionally, Eisai is in contact with the FDA; thus, numerous conversations are happening. I'd simply note that the Phase 1 bioavailability results have previously been made public. As I said before, I've already shared those. And per my earlier comments, right now they're examining the 720-milligram weekly fixed dose, which is under evaluation; however, the timelines and specifics of whatever else the package may require have not been disclosed. So I'd suggest we simply await that disclosure, and once it's suitable, we'll provide it. Still, this is a tremendously important undertaking, and it continues.
Michael Yee
analystHey, thank you. Morning. Returning to what was said regarding CMS reimbursement and the need to hold off for CTAD data, perhaps you might explain which routes or kinds of dialogue, if any, or what strategy you're able to pursue with CMS to create pressure for speed — could that involve patient advocacy organizations, are you all working diligently toward that, or do they simply recognize that there's obviously a shift compared with the ADUHELM circumstances from twelve months ago and they'll move quickly. Thanks.
Michel Vounatsos
executiveEisai, then, takes the lead when it comes to dealing with regulators and payers. And based on our understanding, Eisai has already begun its engagement with CMS. Thus, this activity falls under their responsibility. And right now, I won't share additional specifics. Yet that engagement exists, and that matters most.
Robyn Karnauskas
analystThanks. There are two parts to what I want to ask. First, we keep hearing that Lilly currently has a huge footprint and a lot of doctors' mind share in this area. And Mike, you said something about — I'm trying to figure out your meaning — that you believe we'll see more, and that spending will increase alongside revenue. Could you expand on that a bit? After all, you'll be facing competitors here. Then a quick one for Priya: we also hear about tau pathology, that perhaps you don't want to run trials in patients who already have a beta plaque along with tau — a few things there.
Michael McDonnell
executiveYes. Let me make clearer what I said earlier. As Eisai builds out the commercialization plan together with us, the aim there, clearly, the first and main objective is to nail the launch and establish an infrastructure that backs the strongest possible launch, and we'll be ready; and clearly, in the case we faced with ADUHELM, when approval came in June of 2021, we had a substantial infrastructure already constructed and set to go. And then clearly, we ran into major delays. What I was getting at is that we'd hope that wouldn't happen again and that we'd have the right infrastructure in place to back a successful launch; that's priority one. And then ideally, we wouldn't go through delays of that kind; and so you'd see spending rise ahead of revenue, but the gap wouldn't be as big as it was with ADUHELM.
Priya Singhal
executiveI'd like to jump in on that as well, Robyn. Appreciate it, Mike. Let me build on what was said. When it comes to physicians and their attention, my view is that this area is clearly changing at a very fast pace scientifically. Lecanemab, in my view, has shown that clearing plaques can translate into a clinical effect, and that point is going to matter a great deal. Another thing I want to mention is that the safety profile will be extremely, extremely significant in this context. Take lecanemab as an example: the ARIA rates we're seeing come in at roughly 21%. That has fallen within what we would expect. I believe this, alongside the efficacy findings, will be something physicians need to weigh, so on the whole, while the question may have leaned a bit more toward the launch, my answer would be that physician attention will hinge on the data, and in my view the data from the other anti-amyloid therapies still needs to be reviewed before we can determine what will be meaningful. The other element here, I think, is that we regard ourselves as pioneers. We have this highly encouraging data. Our view is that this is a very wide-ranging and complicated patient population, and the need and unmet need are extremely, extremely high. So we see this as a very significant area where we <<inaudible>> a difference to patients; and then Robyn, regarding the second question, could you clarify it for me? I didn't quite hear it. You cut out near the end.
Robyn Karnauskas
analystYeah, apologies. Regarding tau pathology, a number of researchers hold the view that plaque must be cleared prior to administering tau therapy. Put another way, tau might not be effective on its own. Given what we now know about the biology, you might actually have to pair it with lecanemab. As for all those ongoing studies, 080 included, how do you view the possibility that they could fail since you truly need to remove plaque using an A-beta medication such as lecanemab?
Priya Singhal
executiveUnderstood. Let me take a step back and say that clearly, amyloid pathology matters a great deal. Our position is also that it may sit upstream of tau pathology; and through aducanumab — using our aducanumab data — we were able to demonstrate the effect on phospho-related tau and similar markers. So, in our view this cascade as a whole will prove quite significant. That said, I believe you're correct that perhaps what lies ahead for Alzheimer's disease concerns when intervention happens, which I touched on already, and that is an entirely separate question. It's also possible, though, that a single kind of strategy might not be sufficient. What we're asking ourselves is how to remain highly systematic and methodical in our approach. With lecanemab, we have by now shown that aggregated plaque does get removed, producing a clinical effect. And I believe Eisai also conveyed earlier in the year that, drawing on Phase 2b data plus modeling, this might translate into preservation of roughly 2 to 3 years before patients advance to considerably more severe Alzheimer's stages. That rests on modeling and Phase 2 data, and I'm aware they've stated publicly they'll conduct this same kind of analysis using Phase 3 data. So, I'd say we're achieving meaningful progress. Beyond that, we're separately working on BIIB080, for which our Phase 1b trial yielded highly encouraging results, demonstrating a reduction of tau that was dose and time-dependent. Our belief is that it targets every form of tau. So we're currently starting a Phase 2; yet you're entirely right. We'll be examining numerous different strategies for helping patients in the best manner we possibly can. So yes, every biology deserves consideration, but we must proceed step by step and stay systematic about it.
Michel Vounatsos
executiveAlso, let me jump in regarding mind share—the epidemiology here is massive. When it comes to what still needs building on the infrastructure side, there's a tremendous amount of work, and every one of us is glad to see other companies putting in effort. To speak to lecanemab in particular, I realize that a number of you have had conversations with scientific leaders. We've had discussions with <<inaudible>> as well as clinicians. From everything we're hearing, the response has been quite favorable. Ultimately, though, what will separate these compounds is efficacy at 6 months and then extended across an 18-month study, along with safety. That said, right now we're happy to see any and all efforts aimed at getting the market ready for patients who need it.
Jay Olson
analystHi there, I appreciate you fielding my question, and congratulations on the Clarity AD findings. What I'd like to understand is what possibility exists for the work you're doing alongside Denali, and in what way you intend to make use of that company's TV platform when it comes to A Beta antibodies — lecanemab and ADUHELM included. Given that we now have favorable clear DAD data, is it your view that enhanced brain penetration might lead to a better therapeutic profile for A Beta antibodies? Also, how long until a candidate gets nominated out of the TV program? Many thanks.
Priya Singhal
executiveJay, thank you — that's an excellent question. The one thing I'm able to tell you is that a review is underway across the whole portfolio, and we're examining a number of our current partnerships to determine how we might genuinely advance and capitalize on the power of this data along with the power of the biological hypothesis we've observed. On the Denali TV platform, I'm not in a position to say anything further. That said, nothing has been ruled out; we intend to scrutinize all of it extremely closely, and once things turn relevant and suitable, we will share announcements. Thank you.
Phil Nadeau
analystMorning, and thanks for taking our questions. I have a follow-up about what we learned from the aducanumab launch. What is Biogen thinking these days regarding lecanemab's price? Given the better data, would you expect a premium price compared to ADUHELM, or a discount given the pushback? And recognizing that Eisai has the final say on all commercialization decisions, what part will Biogen play when it comes to setting lecanemab's price? Thank you.
Michel Vounatsos
executiveAs you can imagine, we're not able to comment. That decision belongs to Eisai, and we won't interfere with this process.
Marc Goodman
analystYeah. Can you provide a bit more detail regarding SPINRAZA outside the US — what were the underlying trends? Anything on price increases or favorable pricing trends in that region? And then, Priya, could you simply verify whether the subcutaneous dose is 720 weekly, and is that the one where the dosing regimen is still being worked on?
Michel Vounatsos
executiveI believe your question concerned SPINRAZA outside the US?
Marc Goodman
analystYes.
Michel Vounatsos
executiveYes, so there are 2 kinds of dynamics we're seeing. There's momentum in Europe that's getting slowed by risdiplam's launch; however, we're providing data about patients switching — patients in the U.S. moving from plan back to SPINRAZA because of efficacy. So I believe — and we're gaining knowledge from the US; so it's only a question of time; we're gaining knowledge from the US. The US results make us very happy; and we think this turns into a model that other continents ought to learn from; and outside core Europe, we're seeing volume grow very quickly, but pricing isn't the same. So that's the momentum outside the US. On the whole, the US results make us very happy, since we can see SPINRAZA returning, and we think the product will get back its momentum and grow steadily. Mike, would you like to add anything?
Michael McDonnell
executiveRight. One thing I'd tack on — and Mark, your question really seemed aimed more at OUS — is this. We said the US was flat, and for OUS as a whole there was a slight decrease, yet once you take FX out and look at constant currency, you actually find growth. That growth, tying back to what we laid out in our prepared remarks, came alongside a small drop in volume driven mainly by competition in markets such as Germany, Canada, and Japan. On top of that we had some timing items — Russia, Brazil, a handful of others — which was partly offset by higher volume in China. That said, price increases in several European markets more than made up for the volume. So unpacking it: you had modest volume declines that were slightly more than offset by price increases, and then FX worked against you in OUS.
Priya Singhal
executiveAlright, let me close out on that second item very briefly. Regarding your second question, as I understand it, Eisai has stated that the fixed weekly amount of 720 milligrams represents the dosage demonstrating equivalence to an intravenous regimen of 10 milligrams per kilogram given every two weeks. Moreover, that same amount now appears for the auto-injector trial that was announced not long ago. I believe that addresses what you asked. If your point was actually something else, please let me know.
Marc Goodman
analystNo, that’s it. Thank you.
Priya Singhal
executiveThank you.
Marc Goodman
analystYes, thank you.
Chris Schott
analystThanks a lot for taking our questions. While we're waiting on the subcutaneous version and the maintenance programs, could you give us more detail about what's happening with the two-week IV regimen for lecanemab? Leaving reimbursement to one side, how difficult do you expect this to be from a commercial and infrastructure perspective? And I realize you aren't talking about timing, but do you see this as a fairly brief period in which this current dosing approach would be used, or might we be facing this situation for a long stretch? Thank you.
Priya Singhal
executiveOkay. So, on the whole, the results we've observed with the 10-milligram per kg dose given every two weeks have been very good. One key thing I'd highlight as highly relevant: that split shows up at the six-month mark — with no titration needed that early — and it keeps widening in absolute terms all the way to the 18-month primary endpoint readout in Clarity AD. So the data is quite encouraging. As the whole Alzheimer's disease infrastructure has gotten built out, it's going to matter a great deal that physicians actually see these patients. If that was the question, we wouldn't call it a drawback; no, we don't view it that way. That said, we're doing everything. Eisai is heading up this work, and our goal is to ensure we're prioritizing what's convenient for patients — that's the whole rationale behind developing a subcutaneous version. Because of that, I'm not able to say anything further about the duration of the intravenous phase or the point at which a switch to subcutaneous would occur. That said, we are examining every one of these dimensions with great care, both from a broad perspective and in fine detail, while we put together the clinical development program with all of these considerations in view. Taking everything together, our view is that during the initial period, having patients come into the clinic once every 14 days will genuinely be essential.
Paul Matteis
analystThank you very much. Given what you've seen in practice with ADUHELM, how would you describe the current state of infusion capacity in neurology clinics as we approach the lecanemab launch? What does that capacity look like right now? And how much expansion do you believe is required before access becomes substantially wider down the road?
Michel Vounatsos
executiveWhat ADUHELM showed us is that the system demonstrated a degree of flexibility, reallocating portions of existing infusion centers toward possibly ADUHELM at that point if reimbursement had come through; reimbursement never materialized, so that scenario didn't occur. More broadly, my view is that scaling up is necessary, and capacity needs to be considerably bigger. That said, what we learned indicates the system could be nimble and adaptive given the capacity available at present.
Geoff Meacham
analystMorning, everyone, and thanks a lot for sending in your questions. I have one more thing to ask regarding the money being spent on the lecanemab rollout. After the restructuring you carried out earlier this year, could you discuss which manufacturing assets might be shifted to new uses, or perhaps certain commercial investments originally made for ADUHELM that could be redirected toward launching lecanemab? I am simply attempting to understand the scale of the spending relative to uptake throughout next year.
Michel Vounatsos
executiveMike?
Michael McDonnell
executiveSure, let me offer a few points on that, Geoff, and thanks for raising it. First, regarding manufacturing: we operate a sizable site in Raleigh, North Carolina, plus a fairly recent one in Solothurn, Switzerland. That Solothurn site is going to be mostly focused on our Alzheimer's disease products, which at this stage means building up inventory ahead of the lecanemab launch. As of the quarter's close, I believe we were holding a bit more than $100 million in inventory. The efficiency of that site, you could say, is closely linked to how the lecanemab launch goes, and if ADUHELM gains more market traction, we'd be able to use that site too. So that's where things stand. Some capacity will sit idle. You saw roughly $12 million of that this quarter. As that product ramps, we'll keep having to absorb some idle capacity charges. On the commercial side, not much can be repurposed from ADUHELM. As we've stated previously, we chose to wind that infrastructure down. The gap between getting the NCD in April of 2022 and lecanemab reaching full commercialization was simply too long to keep that infrastructure in place. So the bulk of it has been removed as part of the $1 billion in cost savings we've committed to. That means lecanemab commercialization will mostly involve a fresh ramp and freshly built infrastructure.
Mike Hencke
executiveThat concludes our call for this morning. Thank you, everyone, for joining us.
Operator
operatorThis concludes today's call. Thank you for your participation. You may now disconnect.
Read the full transcript via the API
You're viewing the first half of this call. Get the complete Biogen Inc. transcript — plus 132,000+ transcripts from 7,000+ companies, speaker segments, AI summaries and full-text search — through the EarningsCalls.dev API.
Get the API View API docs →This call discussed
For developers and AI pipelines
Programmatic access to Biogen Inc. earnings transcripts and 132,000+ others is available through the
EarningsCalls.dev REST API. Plans from $39.99/month — full transcripts, speaker segments,
full-text search, and the recently-added /api/v1/transcripts/recent polling endpoint for ETL pipelines.
More tools for stock research
OptionsBell: an unusual options activity scanner that tracks options flow across all US stocks and emails you when large trades appear in Biogen Inc. or any ticker on your watchlist.
StockMarketScan: a stock screener with alerts: 24 pre-built screens refreshed every 5 minutes, watchlists and email notifications. Both offer API and MCP access and fair monthly pricing.